Evofem Executes 1-for-1,500 Reverse Split, Cutting Shares From 132.5M to ~88,353
Summary
Evofem's 1-for-1,500 reverse split took effect November 18, 2026, reducing outstanding shares from about 132.5 million to roughly 88,353 to free up authorized shares for its convertible instruments. It does nothing to address the $44 million of debt due December 1, 2026.
Key Events · Corporate Governance and Compliance · EVFM
-
1-for-1,500 Reverse Split Effective
Every 1,500 pre-split shares converted into one share at the open on November 18, 2026, with par value unchanged at $0.0001.
-
Share Count Cut to ~88,353
Outstanding common stock fell from approximately 132,530,081 shares as of the November 17, 2026 record date to approximately 88,353 shares.
-
Authorized Shares Freed for Dilution
The company states the split is intended to ensure enough authorized shares to cover the common shares underlying its financial instruments on a fully diluted basis; total authorized Common Stock remains 3,000,000,000 shares.
-
Fractional Holders Cashed Out at $0.0043
Holders entitled to fractional shares receive cash equal to the fraction multiplied by the November 17, 2026 closing price of $0.0043, rounded down to the nearest cent.
Analysis · EVFM · Life Sciences
The 1-for-1,500 reverse split is now effective, collapsing roughly 132.5 million shares into about 88,353. Evofem says the move is to ensure enough authorized shares to cover the common shares underlying its financial instruments on a fully diluted basis — a mechanical fix for a company whose stock trades at fractions of a cent. It does not raise cash or reduce the $44 million of debt maturing December 1, 2026 that the Q3 10-Q flagged against only $0.3 million of restricted cash; the balance-sheet problem is unchanged. The 20-business-day EVFMD ticker and new CUSIP are administrative, but the fractional-share cash-out at $0.0043 forces small holders out at the pre-split price.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVFM was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $569.9K. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.